Disease staging, whereby the spatial extent and load of brain pathology are used to
estimate the severity of Alzheimer disease (AD), is pivotal to the gold-standard …

Two phase-III clinical trials with anti-amyloid peptide antibodies have met their primary goal,
ie slowing of Alzheimer's disease (AD) progression. However, antibody therapy may not be …

Abstract The National Institute on Aging and the Alzheimer's Association convened three
separate work groups in 2011 and single work groups in 2012 and 2018 to create …

Animal and computational models of Alzheimer's disease (AD) indicate that early amyloid-β
(Aβ) deposits drive neurons into a hyperactive regime, and that subsequent tau depositions …

Background Recently developed blood markers for Alzheimer's disease (AD) detection have
high accuracy but usually require ultra-sensitive analytic tools not commonly available in …

Biomarkers that predict the clinical onset of Alzheimer's disease (AD) enable the
identification of individuals in the early, preclinical stages of the disease. Detecting AD at this …

Blood biomarkers have emerged as accessible, cost-effective, and highly promising tools for
advancing the diagnostics of Alzheimer's disease. However, transitioning from cerebrospinal …

Background Antibody-based immunoassays have enabled quantification of very low
concentrations of phosphorylated tau (p-tau) protein forms in cerebrospinal fluid (CSF) …

Background The blood-based biomarkers are approaching the clinical practice of
Alzheimer's disease (AD). Chronic kidney disease (CKD) has a potential confounding effect …

Predominant limbic degeneration has been associated with various underlying aetiologies
and an older age, predominant impairment of episodic memory and slow clinical …